dna-cleaving

Phleomycin is one of the anticancer glycopeptide antibiotics which cause DNA cleavage. It is similar to Bleomycin which binds and intercalates DNA to damage the integrity of the double helix.

Deglycobleomycin is an RNA cleaving agent that targets r(CUG) repeat sequences. By binding with small molecules that recognize r(CUG)exp, Deglycobleomycin can selectively cleave r(CUG)exp. Its efficiency in cleaving DNA is considerably lower than that of Bleomycin A5(Pingyangmycin), but it exhibits enhanced selectivity for r(CUG)exp. Deglycobleomycin is useful for research on diseases associated with r(CUG) repeat expansions, such as myotonic dystrophy type 1, and the development of drugs aimed at precise targeting and cleavage of pathogenic RNA.

CP 67804 enhances topoisomerase II-mediated DNA cleaving.

Azamitosene is a DNA cleaving agent exhibiting G and A base specificity. Azamitosene may exhibit a growth inhibitory effect on human gastric cancer cells.

Phleomycin D1 (PLM D1), a glycopeptide antibiotic in the Bleomycin/Phleomycin family, induces cell death by binding to and cleaving DNA [1] [2] [3].

Serratia marcescens nuclease (EC 3.1.30.2) is a non-specific endonuclease enzyme derived from the bacterium Serratia marcescens that exhibits potent digestive activity toward both DNA and RNA substrates by cleaving phosphodiester bonds, granting it broad utility in molecular biology applications for nucleic acid degradation and removal.

AsCas12a Nuclease is a CRISPR nuclease capable of specifically cleaving double-stranded DNA. It is used in gene editing research.